<DOC>
	<DOCNO>NCT02041715</DOCNO>
	<brief_summary>Phase 1 , single-center , placebo-controlled , single-blind , first-in-human , single ascend dose ( SAD ) study follow multiple-dose cohort healthy male female subject .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetic First Human ( FIH ) Study Intravenous ( IV ) TKM-100802</brief_title>
	<detailed_description>Approximately 20 male female healthy adult subject , 18 50 year age time dosing , participate study . The SAD phase study plan 4 cohort 4 subject ( 3 receive TKM-100802 1 receive saline ) cohort . Additional cohort may enrol SAD phase MTD establish initial 4 cohort . In multiple-dose phase , one cohort plan 4 subject ( 3 receive TKM-100802 1 receive saline ) maximum dose 0.24 mg/kg TKM-100802 .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Hemorrhagic Fever , Ebola</mesh_term>
	<criteria>1 . Informed nature study able read , review , agree , sign inform consent document Screening . 2 . Able comply protocolspecified visit schedule requirement . 3 . Healthy male female subject 18 50 year age , inclusive , time dose . 4 . Body mass index ( BMI ) 22 kg/m2 35 kg/m2 , inclusive , weigh least 110 lb ( 50 kg ) . 4a . Systolic blood pressure ≥110 mmHg ( subject seat position leg dangle ) also , 5 minute move supine seat position drop systolic pressure must &lt; 15 mmHg increase pulse &lt; 10 bpm . 5 . Judged PI good health document medical history , physical examination ( include may limited evaluation cardiovascular , gastrointestinal , respiratory central nervous system ) , vital sign assessment , 12lead ECG , clinical laboratory assessment , general observation . Any abnormality deviation outside normal range clinical testing ( laboratory test , ECG , vital sign ) repeat discretion PI judge clinically significant , subject may consider study participation . 6 . Adequate hepatic , renal , hematologic clot function define total bilirubin , AST , ALT , serum creatinine , Ddimer International normalize ratio ( INR ) within normal range determine PI Sponsor Medical Monitor . 7 . Female subject must one following : naturally postmenopausal ( menses ) &gt; 2 year document FSH level &gt; 40 mIU/mL ; document history ovarian failure ; surgically postmenopausal ( bilateral oophorectomy hysterectomy ) . Female subject surgically postmenopausal must provide documentation bilateral oophorectomy hysterectomy prior Day 1 dose eligible participation study ; Women childbearing potential ( FSH ≤40 mIU/mL ) must negative serum hCG Screening , negative urine pregnancy test prior first study treatment , must agree utilize highly effective contraception method ( 2 separate form contraception , 1 must effective barrier method , nonheterosexually active , vasectomized partner ) Screening throughout duration study treatment 1 month last administration study treatment . 8 . Male subject sexually active must willing use effective barrier contraception ( e.g. , condom spermicide ) heterosexual intercourse Screening throughout duration study treatment 1 month last dose study treatment . 1 . Evidence history clinically significant hematologic , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic allergic disease Screening medication comorbidity accord PI Sponsor Medical Monitor preclude subject participation clinical study . 2 . Reports uncontrolled psychiatric disorder neurologic disease seizure disorder control medication . 3 . Subject history , exist clinically significant cardiovascular disease ( example , uncontrolled hypertension , unstable angina , congestive heart failure serious cardiac arrhythmia ) . In addition New York Heart Association Functional Classification Class II great exclude . 4 . Reports history coronary heart disease ( CHD ) , CHDequivalent disease CHD risk &gt; 20 % designate National Cholesterol Education Program Adult Treatment Panel III . 5 . Current diagnosis know history liver disease ( e.g. , acute chronic hepatitis liver cirrhosis ) . 6 . History allergy cosyntropin ( MAD cohort ) . 7 . Presence clinically significant result laboratory test , vital sign assessment ECGs judge PI . 8 . Reports receive investigational drug , biologics , device , antiviral drug within 28 day prior study treatment plan use course study . 9 . Reports receive naturopathic medication , herbal supplement , lipid lower therapy within 28 day prior study treatment plan use course study . 10 . A medical condition require prescription treatment would unsafe discontinue . 11 . Recent treatment alternative therapy , view PI Sponsor Medical Monitor , could potentially confound clinical laboratory assessment . 12 . Demonstrates mark baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTc interval &gt; 450 m ) . 13 . Reports concomitant use medication prolongs QT/QTc interval . 14 . Reports history additional risk factor torsades de pointes ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) . 15 . When confirm upon additional testing , demonstrate reactive screen hepatitis B surface antigen , hepatitis C antibody , HIV antibody . 16 . Reports infection require antibiotic therapy within 28 day Screening ( determine PI ) . 17 . Reports history Ebola virus exposure . 18 . Reports occupational health risk exposure Ebola virus know higher general population . 19 . Reports know suspected hypersensitivity previous severe reaction constituent TKM100802 include oligonucleotide lipidbased product , liposomal drug product , phospholipidbased product ( parenteral nutrition , Intralipid ) . 20 . Reports history clinically significant allergy include food drug allergy . 21 . Demonstrates positive drug alcohol screen . 22 . Reports history drug alcohol addiction abuse within past 1 year . 23 . Subject unwilling refrain alcohol consumption completely restrict completely restrict , unwilling limit alcohol consumption 2 drinks/day , &lt; 12 drinks/week male 1 drink/day , &lt; 6 drinks/week female ( 1 drink equal 12 ounce beer , 5 ounce wine , 1 ounce liquor ) . 24 . Reports donate blood within 28 day prior study treatment . All subject advise donate blood 4 week complete study . 25 . Reports donate plasma ( e.g. , plasmapheresis ) within 28 day prior study treatment . All subject advise donate plasma 4 week complete study . 26 . Demonstrates , opinion study staff , vein unsuitable repeated venipuncture IV infusion ( e.g. , vein difficult locate , access , puncture ; vein tendency rupture puncture ) . 27 . Pregnant , lactating , breastfeeding , intend become pregnant course study . 28 . Demonstrates positive pregnancy screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Virus Diseases</keyword>
	<keyword>Hemorrhagic Fever , Ebola</keyword>
	<keyword>Hemorrhagic Fevers , Viral</keyword>
	<keyword>RNA Virus Infections</keyword>
	<keyword>Filoviridae Infections</keyword>
	<keyword>Mononegavirales Infections</keyword>
</DOC>